DE2348897C3 - In die Atmungswege verabreichbarer Impfstoff zur Immunisierung von Tieren gegen Mycoplasmose der Atmungsorgane - Google Patents
In die Atmungswege verabreichbarer Impfstoff zur Immunisierung von Tieren gegen Mycoplasmose der AtmungsorganeInfo
- Publication number
- DE2348897C3 DE2348897C3 DE2348897A DE2348897A DE2348897C3 DE 2348897 C3 DE2348897 C3 DE 2348897C3 DE 2348897 A DE2348897 A DE 2348897A DE 2348897 A DE2348897 A DE 2348897A DE 2348897 C3 DE2348897 C3 DE 2348897C3
- Authority
- DE
- Germany
- Prior art keywords
- mycoplasma
- vaccine
- suspension
- killed
- respiratory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 241001465754 Metazoa Species 0.000 title claims description 13
- 210000002345 respiratory system Anatomy 0.000 title claims description 9
- 229940038578 respiratory vaccine Drugs 0.000 title description 2
- 239000000725 suspension Substances 0.000 claims description 79
- 229960005486 vaccine Drugs 0.000 claims description 79
- 241000204022 Mycoplasma gallisepticum Species 0.000 claims description 30
- 230000003053 immunization Effects 0.000 claims description 24
- 238000002649 immunization Methods 0.000 claims description 23
- 210000002966 serum Anatomy 0.000 claims description 20
- 239000003381 stabilizer Substances 0.000 claims description 19
- 241000283707 Capra Species 0.000 claims description 17
- 241000204045 Mycoplasma hyopneumoniae Species 0.000 claims description 15
- CJPQIRJHIZUAQP-MRXNPFEDSA-N benalaxyl-M Chemical compound CC=1C=CC=C(C)C=1N([C@H](C)C(=O)OC)C(=O)CC1=CC=CC=C1 CJPQIRJHIZUAQP-MRXNPFEDSA-N 0.000 claims description 14
- 241000202936 Mycoplasma mycoides Species 0.000 claims description 13
- 244000144977 poultry Species 0.000 claims description 12
- 210000000056 organ Anatomy 0.000 claims description 11
- 230000000241 respiratory effect Effects 0.000 claims description 10
- 102000007562 Serum Albumin Human genes 0.000 claims description 6
- 108010071390 Serum Albumin Proteins 0.000 claims description 6
- 239000012736 aqueous medium Substances 0.000 claims description 5
- -1 polyoxyethylene Polymers 0.000 claims description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- 241001430197 Mollicutes Species 0.000 claims description 4
- 229920000159 gelatin Polymers 0.000 claims description 4
- 235000019322 gelatine Nutrition 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- 108010010803 Gelatin Proteins 0.000 claims description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 claims description 2
- 229920002307 Dextran Polymers 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 150000001720 carbohydrates Chemical class 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 239000001593 sorbitan monooleate Substances 0.000 claims description 2
- 235000011069 sorbitan monooleate Nutrition 0.000 claims description 2
- 229940035049 sorbitan monooleate Drugs 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 40
- 241000204031 Mycoplasma Species 0.000 description 38
- 210000004712 air sac Anatomy 0.000 description 20
- 210000003437 trachea Anatomy 0.000 description 19
- 238000012360 testing method Methods 0.000 description 18
- 241000204003 Mycoplasmatales Species 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 16
- 208000015181 infectious disease Diseases 0.000 description 16
- 201000010099 disease Diseases 0.000 description 15
- 239000000203 mixture Substances 0.000 description 15
- 241000282887 Suidae Species 0.000 description 14
- 210000004072 lung Anatomy 0.000 description 13
- 241000202942 Mycoplasma synoviae Species 0.000 description 12
- 238000007918 intramuscular administration Methods 0.000 description 12
- 210000003205 muscle Anatomy 0.000 description 12
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 11
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 10
- 238000011156 evaluation Methods 0.000 description 10
- 235000013594 poultry meat Nutrition 0.000 description 10
- 239000006285 cell suspension Substances 0.000 description 9
- 239000013068 control sample Substances 0.000 description 9
- 239000001963 growth medium Substances 0.000 description 9
- 241000287828 Gallus gallus Species 0.000 description 8
- 235000013330 chicken meat Nutrition 0.000 description 8
- 238000002955 isolation Methods 0.000 description 8
- 238000009630 liquid culture Methods 0.000 description 8
- 239000007921 spray Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 210000002969 egg yolk Anatomy 0.000 description 7
- 238000005507 spraying Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 102000002322 Egg Proteins Human genes 0.000 description 6
- 108010000912 Egg Proteins Proteins 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 230000000996 additive effect Effects 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 235000013345 egg yolk Nutrition 0.000 description 6
- 229940031551 inactivated vaccine Drugs 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 6
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 5
- 239000001110 calcium chloride Substances 0.000 description 5
- 229910001628 calcium chloride Inorganic materials 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- 230000003449 preventive effect Effects 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 239000008055 phosphate buffer solution Substances 0.000 description 3
- 239000000661 sodium alginate Substances 0.000 description 3
- 235000010413 sodium alginate Nutrition 0.000 description 3
- 229940005550 sodium alginate Drugs 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 208000030270 breast disease Diseases 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000009210 therapy by ultrasound Methods 0.000 description 2
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- 241000606767 Avibacterium paragallinarum Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- 208000014085 Chronic respiratory disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000711450 Infectious bronchitis virus Species 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- VLSOAXRVHARBEQ-UHFFFAOYSA-N [4-fluoro-2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=C(F)C=C1CO VLSOAXRVHARBEQ-UHFFFAOYSA-N 0.000 description 1
- RJFMUPQYHXOTCF-UHFFFAOYSA-M [Na+].CC[Hg].OC1=CC=CC=C1C([O-])=O Chemical compound [Na+].CC[Hg].OC1=CC=CC=C1C([O-])=O RJFMUPQYHXOTCF-UHFFFAOYSA-M 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 229940024545 aluminum hydroxide Drugs 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 229940068840 d-biotin Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000020772 multivitamin supplement Nutrition 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 239000012875 nonionic emulsifier Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229960000380 propiolactone Drugs 0.000 description 1
- FCHXJFJNDJXENQ-UHFFFAOYSA-N pyridoxal hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(C=O)=C1O FCHXJFJNDJXENQ-UHFFFAOYSA-N 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 229960000344 thiamine hydrochloride Drugs 0.000 description 1
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 1
- 239000011747 thiamine hydrochloride Substances 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 210000000216 zygoma Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/544—Mucosal route to the airways
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/826—Bacterial vaccine for avian species, e.g. poultry or other birds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10002872A JPS5540568B2 (cg-RX-API-DMAC7.html) | 1972-10-05 | 1972-10-05 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DE2348897A1 DE2348897A1 (de) | 1974-09-26 |
| DE2348897B2 DE2348897B2 (de) | 1979-06-21 |
| DE2348897C3 true DE2348897C3 (de) | 1980-02-14 |
Family
ID=14263067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2348897A Expired DE2348897C3 (de) | 1972-10-05 | 1973-09-28 | In die Atmungswege verabreichbarer Impfstoff zur Immunisierung von Tieren gegen Mycoplasmose der Atmungsorgane |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US3917819A (cg-RX-API-DMAC7.html) |
| JP (1) | JPS5540568B2 (cg-RX-API-DMAC7.html) |
| AU (1) | AU461928B2 (cg-RX-API-DMAC7.html) |
| BE (1) | BE805570A (cg-RX-API-DMAC7.html) |
| CA (1) | CA1016456A (cg-RX-API-DMAC7.html) |
| DE (1) | DE2348897C3 (cg-RX-API-DMAC7.html) |
| FR (1) | FR2201878B1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB1439407A (cg-RX-API-DMAC7.html) |
| IL (1) | IL43310A (cg-RX-API-DMAC7.html) |
| IT (1) | IT1055538B (cg-RX-API-DMAC7.html) |
| NL (1) | NL159584B (cg-RX-API-DMAC7.html) |
| SU (1) | SU625623A3 (cg-RX-API-DMAC7.html) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60197628A (ja) * | 1984-03-22 | 1985-10-07 | Eisai Co Ltd | マイコプラズマ性肺炎予防治療剤 |
| FR2565825B1 (fr) * | 1984-06-15 | 1990-07-13 | Centre Nat Rech Scient | Vaccin contre les maladies dues a des microorganismes tels que des mycoplasmes, sa preparation et membranes de microorganismes en tant que principe actif |
| US5004607A (en) * | 1987-08-25 | 1991-04-02 | University Of Georgia Research Foundation, Inc. | Method of immunizing poultry |
| DE3881993T2 (de) * | 1987-09-18 | 1993-09-30 | Akzo Nv | Mycoplasma-Impfstoff. |
| HK1000113A1 (en) * | 1989-01-23 | 1997-12-05 | Auspharm International Ltd. | Vaccine composition |
| US5565205A (en) * | 1990-08-16 | 1996-10-15 | Solvay Animal Health, Inc. | Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof |
| USRE39494E1 (en) * | 1992-02-27 | 2007-02-27 | Intervet Inc. | Inactivated mycoplasma hyopneumoniae and uses therefor |
| US5338543A (en) * | 1992-02-27 | 1994-08-16 | Ambico, Inc. | Thimerosal inactivated mycoplasma hyopneumoniae vaccine |
| US5514665A (en) * | 1993-12-30 | 1996-05-07 | University Of British Columbia | Method of preventing or reducing the risk of infection by bacterial pathogens utilizing simple and conjugated dextrans |
| FR2722509B1 (fr) * | 1994-07-15 | 1996-09-20 | Pasteur Institut | Identification de genes codant pour des proteines ayant une activite d'esterase dans differentes souches de mycoplasma mycoides |
| CA2184132C (en) * | 1995-09-21 | 2011-03-15 | Kristina J. Hennessy | An adjuvanted vaccine which is substantially free of non-host albumin |
| US6682746B2 (en) | 1995-09-21 | 2004-01-27 | Kristina J. Hennessy | Adjuvanted vaccine which is substantially free of non-host albumin |
| ZA9710606B (en) * | 1996-12-05 | 1998-06-12 | Akzo Nobel Nv | Non-virulent Mycoplasma synoviae vaccine thereof. |
| TW586934B (en) * | 1997-05-19 | 2004-05-11 | Sumitomo Pharma | Immunopotentiating composition |
| GB0110851D0 (en) * | 2001-05-03 | 2001-06-27 | Mini Agriculture & Fisheries | Vaccine |
| MX2010005014A (es) * | 2007-11-06 | 2010-06-30 | Wyeth Llc | Vacuna viva avirulenta de mycoplasma hyopneumoniae con adyuvante. |
| BR112014022067B1 (pt) | 2012-03-07 | 2022-05-31 | Ceva Sante Animale | Composição compreendendo antígeno e lipopolissacarídeo |
| BR112015003074A2 (pt) | 2012-08-17 | 2017-07-04 | Intervet Int Bv | composição, vacina para proteger um animal contra uma infecção com bactérias leptospira, e, uso de ácido etilenodiaminatetra-acético. |
| US11369671B2 (en) * | 2012-09-10 | 2022-06-28 | Galenbio, Inc. | Vaccine to prevent mycoplasmal infections in waterfowl |
| EP2938747B1 (en) | 2012-12-28 | 2019-05-01 | Boehringer Ingelheim Vetmedica GmbH | Method of making a mycoplasma vaccine |
| CN110227151B (zh) * | 2012-12-28 | 2024-06-14 | 勃林格殷格翰动物保健有限公司 | 包含支原体抗原的免疫原性组合物 |
| CN103479995B (zh) * | 2013-10-08 | 2015-04-15 | 南京天邦生物科技有限公司 | 鸡毒支原体、鸡滑液囊支原体二联灭活疫苗的制备方法 |
| CN103495160B (zh) * | 2013-10-08 | 2015-11-18 | 南京天邦生物科技有限公司 | 鸡滑液囊支原体灭活疫苗的制备方法 |
| CN104324370B (zh) * | 2014-09-30 | 2019-12-20 | 普莱柯生物工程股份有限公司 | 疫苗组合物及其制备方法和应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1074920A (en) * | 1965-04-21 | 1967-07-05 | Pfizer & Co C | Growth medium for mycoplasma pneumoniae and vaccine production |
-
1972
- 1972-10-05 JP JP10002872A patent/JPS5540568B2/ja not_active Expired
-
1973
- 1973-09-05 CA CA180,347A patent/CA1016456A/en not_active Expired
- 1973-09-11 AU AU60213/73A patent/AU461928B2/en not_active Expired
- 1973-09-17 US US397909A patent/US3917819A/en not_active Expired - Lifetime
- 1973-09-21 NL NL7313052.A patent/NL159584B/xx not_active IP Right Cessation
- 1973-09-25 IL IL43310A patent/IL43310A/xx unknown
- 1973-09-28 DE DE2348897A patent/DE2348897C3/de not_active Expired
- 1973-09-28 FR FR7334828A patent/FR2201878B1/fr not_active Expired
- 1973-09-28 GB GB4551473A patent/GB1439407A/en not_active Expired
- 1973-09-28 SU SU731966657A patent/SU625623A3/ru active
- 1973-09-28 IT IT69866/73A patent/IT1055538B/it active
- 1973-10-02 BE BE136262A patent/BE805570A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JPS4955822A (cg-RX-API-DMAC7.html) | 1974-05-30 |
| FR2201878A1 (cg-RX-API-DMAC7.html) | 1974-05-03 |
| IL43310A0 (en) | 1973-11-28 |
| IL43310A (en) | 1978-01-31 |
| NL159584B (nl) | 1979-03-15 |
| FR2201878B1 (cg-RX-API-DMAC7.html) | 1977-11-04 |
| DE2348897B2 (de) | 1979-06-21 |
| AU6021373A (en) | 1975-03-13 |
| AU461928B2 (en) | 1975-06-12 |
| GB1439407A (en) | 1976-06-16 |
| DE2348897A1 (de) | 1974-09-26 |
| CA1016456A (en) | 1977-08-30 |
| IT1055538B (it) | 1982-01-11 |
| US3917819A (en) | 1975-11-04 |
| NL7313052A (cg-RX-API-DMAC7.html) | 1974-04-09 |
| BE805570A (fr) | 1974-02-01 |
| JPS5540568B2 (cg-RX-API-DMAC7.html) | 1980-10-18 |
| SU625623A3 (ru) | 1978-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2348897C3 (de) | In die Atmungswege verabreichbarer Impfstoff zur Immunisierung von Tieren gegen Mycoplasmose der Atmungsorgane | |
| DE69027112T2 (de) | Impfstoffzusammensetzung | |
| DE69128361T3 (de) | Impfstoff gegen die pneumonie bei schweinen und verfahren zu seiner herstellung | |
| DE69713408T2 (de) | Streptococcus equi Impstoff | |
| DE3911442A1 (de) | Impfstoff-praeparation | |
| DE69925371T2 (de) | Impfstoff für geflügel | |
| DE60008895T2 (de) | Makrolid-antibiotika und behandlung von pasteurellosis | |
| EP0304786A2 (de) | Intranasale Impfung von Pferden mit inaktivierten Mikroorganismen oder antigenem Material | |
| DE69232969T2 (de) | Methode zur herstellung von gram-negativen bakteriellen vakzinen | |
| DE2836507A1 (de) | Lebendes vaccin gegen pasteurella multocida | |
| DE69216732T2 (de) | Impfstoff gegen den Geflügelanämieerreger | |
| CH664497A5 (de) | Vakzine zur behandlung der harnwegsinfektionen. | |
| DE2212277C3 (de) | Verfahren zur Herstellung einer Totvaccine gegen infektiöse atrophische Rhinitis der Schweine | |
| DE69131525T2 (de) | Pasteurella multocida toxoid enthaltende impfstoffe | |
| EP0564620B1 (de) | Dermatomykose-vakzine | |
| DE60031243T2 (de) | Impfstofformulierung gegen tuberkulose mit monoglyceriden oder fettsäuren als adjuvant | |
| DE2823346C2 (de) | Verwendung von Glycinderivaten zur Herstellung von antiviriellen Mitteln | |
| DE69116606T2 (de) | Bacterin zur Behandlung von Necrophorum-Krankheiten und Verfahren zur Herstellung | |
| DE2120929A1 (de) | Impfstoff für Geflügel gegen die Mareksche Hühnerlähme und Verfahren zu seiner Herstellung | |
| DE69615772T2 (de) | Milder Newcastle-Krankheitsimpfstoff | |
| DE2445819A1 (de) | Verfahren zur herstellung stabiler, gegen seruminhibitoren resistenter h tief 3 n tief 2 -influenzavirusstaemme und diese virusstaemme enthaltende vakzinen | |
| DE2816942C2 (de) | Impfstoff gegen Rhinitis atrophicans beim Schwein | |
| DE69615656T2 (de) | Aviären infektiösen anämie mastgeflügel impfstoff | |
| DE69231724T2 (de) | Fischimpfstoff gegen infektion mit aeromonas salmonicida | |
| DE60213785T2 (de) | Saponin inaktivierte mykoplasma impfstoffe |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C3 | Grant after two publication steps (3rd publication) | ||
| 8339 | Ceased/non-payment of the annual fee |